Best Continuous Glucose Monitors (CGMs) of 2026: Physician-Reviewed Comparison

Quick Answer — Best Continuous Glucose Monitors (CGMs) in 2026:

Best For	Device	MARD	Prescription?
Overall accuracy	Dexcom G7	8.2% (FDA K213369)	Yes
Type 2 / longest wear	FreeStyle Libre 3	7.9% (FDA K221503)	Yes
No prescription needed	Dexcom Stelo	9.0%	No — OTC
Type 1 / closed-loop	Tandem t:slim X2 + Control-IQ	Pump-integrated	Yes
Athletes / predictive alerts	Medtronic Guardian 4	8.7% (FDA K210691)	Yes

Reviewed by Dr. Rishav Das, M.B.B.S. (ORCID: 0009-0007-2692-4542) | Based on FDA 510(k) pivotal trial data, peer-reviewed clinical trials, and 2026 Medicare coverage criteria.

The best continuous glucose monitor for most people in 2026 is the Dexcom G7 — it achieves 8.2% MARD in FDA pivotal trial data, is cleared for ages 2 and older, works with Medicare and most commercial insurance, and has a 30-minute warm-up, the fastest in its class. The FreeStyle Libre 3 (7.9% MARD) is the most accurate CGM currently approved in the US and is the better choice for Type 2 patients prioritizing cost efficiency with insurance. If you do not use insulin and want to skip the doctor’s office entirely, the Dexcom Stelo is the only FDA-approved OTC CGM — available at CVS, Walgreens, and Dexcom.com for approximately $89/month.

If you were recently diagnosed, use insulin, or are selecting a device for a family member — use the 60-second Quick-Pick Guide below, then read the section written for your specific situation.

Quick-Pick CGM Guide: Find Your Best Match in 60 Seconds

Answer these three questions to identify your device:

1. Do you use insulin?

• Yes, for Type 1 diabetes → Best CGM for Type 1 Diabetes: Tandem t:slim X2 + Control-IQ
• Yes, for Type 2 diabetes → Best Overall CGM: Dexcom G7
• No — I manage with diet, exercise, or oral medication → Best OTC CGM: Dexcom Stelo
• I’m not sure → Read How to Choose the Right CGM: Step-by-Step Decision Framework

2. Do you have insurance coverage for a prescription CGM?

• Yes → Best Overall: Dexcom G7 or Best for Cost Efficiency: FreeStyle Libre 3
• No → Best Without Insurance: Dexcom Stelo ($89/month, no Rx)
• I need help navigating insurance → CGM Cost Breakdown and Prior Authorization Guide

3. Are you choosing for a family member?

Still deciding → Start with the Step-by-Step Decision Framework

Child with Type 1 → Best CGM for Parents Monitoring a Child with Type 1

Elderly parent with Type 2 → Best CGM for Elderly Parents

How We Evaluate CGMs: Clinical Accuracy Standards and Selection Criteria

Our evaluation process is based on:

Methodology Transparency: See our About page for detailed editorial standards and conflict-of-interest disclosures for full methodology and procurement transparency.

Device selection criteria and accuracy data are evaluated under our published device evaluation methodology, including reference equipment specifications, sample standards, and error metrics.

CGM Glossary: MARD, Calibration, and Key Terms Explained

Calibration: Some older devices need you to do finger pricks to “teach” the sensor. Newer devices don’t require this.

MARD (Mean Absolute Relative Difference): How accurate the device is. Lower percentage = more accurate. Under 10% is excellent. In plain English: A 9% MARD means the device reading is within 9% of your actual blood sugar 95% of the time.

HbA1c: Your average blood sugar over 2-3 months. Doctors use this to track diabetes control. Think of it like your diabetes “report card.”

CGM vs. BGM: Continuous Glucose Monitor (reads sugar every 1-5 minutes automatically) vs. Blood Glucose Monitor (finger prick device you use manually).

Best Overall CGM: Dexcom G7 — Physician Review (8.2% MARD)

Best for: Adults with Type 1 or Type 2 diabetes who use insulin, want Medicare or commercial insurance coverage, and prioritize clinical accuracy and the shortest sensor warm-up time in the category.

The Dexcom G7 is the best overall continuous glucose monitor available in 2026 for most insulin-using patients. It achieved a MARD of 8.2% in its FDA pivotal trial (510(k) clearance K213369) — within the FDA’s ≤10% threshold for non-adjunctive use, meaning you can make insulin dosing decisions based on G7 readings without a confirming finger stick. It is cleared for ages 2 and older, integrates with Apple Health, Garmin Connect, and the Dexcom Clarity app, and is the only CGM in its class with a 30-minute sensor warm-up.

Dexcom G7 Key Specifications and FDA Clearance (K213369)

Clinical Accuracy Evidence

The Dexcom G7’s MARD of 8.2% was established across the FDA 510(k) K213369 pivotal trial. In practical terms: if your true blood glucose is 150 mg/dL, the G7 may read between 138 and 162 mg/dL. Over 1 million hours of clinical data support its safety profile across the Type 1 and Type 2 populations. The G7 is compatible with both the Tandem t:slim X2 and Omnipod 5 automated insulin delivery systems, making it the most widely integrated CGM for closed-loop therapy.

In a randomized controlled trial published in the New England Journal of Medicine (Brown et al., 2019, doi:10.1056/NEJMoa1907863), CGM use was associated with a 0.5–1.0% reduction in HbA1c among insulin-using Type 1 adults even without medication changes. The G7’s upgraded sensor algorithm improves low-glucose accuracy relative to its predecessor, the G6.

Dexcom G7 Strengths and Limitations

💬 Real User Experience:
“Since switching to Dexcom G7, I’ve caught 3 nighttime lows that my old finger-stick routine would have completely missed. That’s peace of mind worth paying for.”
— Sarah M., Type 1 for 15 years

Dexcom G7 Monthly Cost: With and Without Insurance (2026)

How to get started with the Dexcom G7:

• Download the Dexcom G7 app (iOS or Android) before your sensor arrives — setup takes under 10 minutes
• Ask your physician for a CGM prescription specifying “Dexcom G7” — bring a printed copy of your most recent HbA1c result
• Submit a prior authorization request through your insurer using CPT code A9277 (CGM sensor) and your diabetes ICD-10 code
• Order through Dexcom.com, your pharmacy, or a durable medical equipment (DME) supplier approved by your insurer

Best CGM for Type 1 Diabetes: Tandem t:slim X2 + Control-IQ System

FDA Approval Status: Approved for Type 1 diabetes management
Prescription Required: Yes (both insulin pump and CGM)

How Closed-Loop Insulin Delivery Works

This is an integrated insulin delivery system, not a standalone monitor. Included here due to significant glucose monitoring advantages for Type 1 users.

Clinical Evidence: Time in Range and HbA1c Outcomes

• Glycemic Control: Mean HbA1c reduction of 0.33% vs. sensor-augmented pump therapy (DCL trial, 2020)
• Time in Range: Increased time in range (70-180 mg/dL) by approximately 11% vs. comparator
• Hypoglycemia Reduction: Reduced time below 70 mg/dL by approximately 40%

Type 1-Specific Advantages and Clinical Considerations

Why This System Excels for Type 1:

• Automated insulin adjustments every 5 minutes based on CGM data
• Predictive low glucose suspend prevents hypoglycemia
• Sleep mode optimization for overnight glucose control
• Exercise mode for activity-related glucose management
• Reduces daily diabetes management burden

Ready to Get Started with Tandem T? Here’s How:

Step 1: Verify Insurance Coverage (15 minutes)
Call the number on your insurance card and ask: “Do you cover Tandem T as durable medical equipment or pharmacy benefit? What’s my copay? Do I need prior authorization?”
Tip: Medicare Part B covers CGMs for insulin users as of 2024. Medicaid coverage varies by state.

Step 2: Get a Prescription (1 doctor visit)
Your doctor needs to prescribe a CGM and provide documentation of your diabetes diagnosis + current treatment. Questions to ask your doctor: Use our downloadable checklist below.

Step 3: Choose Where to Order

• Through insurance: DME (durable medical equipment) supplier or pharmacy benefit
• Out-of-pocket: Tandem T – Manufacturer website, Amazon, or major pharmacy chains
• Compare pricing: DME suppliers often cheaper with insurance; pharmacies faster without insurance

Step 4: Check for Savings Programs

• Tandem T manufacturer patient assistance
• Pharmacy discount cards (GoodRx, SingleCare) if paying out-of-pocket
• Ask about trial programs: Some manufacturers offer first sensor free

Can’t decide yet? Save this comparison (print or email yourself) and discuss with your doctor at your next appointment.

Best CGM for Type 2 Diabetes: FreeStyle Libre 3 — Physician Review (7.9% MARD)

Best for: Adults with Type 2 diabetes (insulin-using or non-insulin) who have commercial insurance, want the most accurate CGM currently approved in the US, and prefer a 14-day sensor life — the longest continuous wear of any CGM in this comparison.

The FreeStyle Libre 3 is the most accurate CGM currently approved in the United States, with a MARD of 7.9% established in FDA 510(k) pivotal trial data (clearance K221503). For Type 2 patients with commercial insurance, it typically costs less per month than the Dexcom G7, carries a 14-day sensor life, and transmits glucose readings automatically via Bluetooth every minute — without requiring scanning. It is cleared for ages 4 and older.

Why FreeStyle Libre 3 for Type 2 and Non-Insulin Patients

For non-insulin-using Type 2 patients who do not qualify for OTC Stelo pricing and have insurance coverage, the FreeStyle Libre 3 delivers the highest clinical accuracy at the lowest prescription cost in this category.

Its 14-day sensor life reduces the cost-per-day compared to the G7’s 10-day sensor. For patients who find fingerstick glucose logs insufficient to identify postprandial spikes or overnight hypoglycemia, real-time continuous alerts from Libre 3 provide actionable data that self-monitoring of blood glucose cannot.

FreeStyle Libre 3 Specifications and FDA Clearance (K221503)

Clinical Evidence for Type 2 Diabetes

In a randomized controlled trial by Haak et al. (Diabetes Therapy, 2017, doi:10.1007/s13300-016-0223-6), flash CGM use was associated with reduced time in hypoglycemia and improved self-monitoring compliance in insulin-treated Type 2 patients. HbA1c reductions of 0.5–1.0% have been reported in non-insulin users adopting CGM-guided behavioral changes (Brown et al., N Engl J Med, 2019, doi:10.1056/NEJMoa1907863).

The 7.9% MARD gives the Libre 3 a meaningful accuracy advantage over the G7’s 8.2% in the hypoglycemic range — where accuracy matters most for safety. At 70 mg/dL, a 7.9% MARD means readings may range from 64–76 mg/dL; an 8.2% MARD ranges from 64–76 mg/dL (minimal difference at low glucose; more notable mid-range).

FreeStyle Libre 3 Strengths and Limitations

💬 Real User Experience:
“I was terrified of technology, but the Libre 3 app is honestly simpler than texting my grandkids. Took me one day to figure out, and now I can’t imagine going back to finger pricks.”
— Robert T., Type 2, age 68

FreeStyle Libre 3 Monthly Cost: With and Without Insurance (2026)

How to get started with the FreeStyle Libre 3:

• Apply the sensor to the back of your upper arm; the 60-minute warm-up begins automatically upon activation
• Ask your physician for a prescription specifying “FreeStyle Libre 3” — not “FreeStyle Libre” (your pharmacy may substitute Libre 2 without specifying)
• Confirm your insurance formulary tier — Abbott offers a copay savings card at FreeStyleLibre.us for commercially insured patients
• Download the LibreLink app (iOS or Android) before your sensor arrives — the sensor activates via the app, not a reader device

Best OTC CGM (No Prescription Required): Dexcom Stelo Review

Yes. The Dexcom Stelo is the first FDA-approved over-the-counter continuous glucose monitor in the United States. Approved in 2024, it is designed for adults with Type 2 diabetes who do not use insulin and for individuals monitoring glucose for prediabetes or general wellness. It is available at CVS, Walgreens, Walmart, and Dexcom.com at approximately $89/month for a 2-pack of 15-day sensors, without a prescription or
doctor’s visit. It is not approved for insulin dosing decisions or Type 1 diabetes.

Best for: Adults with Type 2 diabetes who do not use insulin, individuals monitoring glucose for prediabetes or general metabolic health, and anyone who wants to start using a CGM today without a doctor’s visit.

Who should NOT use Stelo: If you take any form of insulin, have Type 1 diabetes, are pregnant, or plan to make insulin dosing decisions based on CGM readings, Stelo is not approved for your use case. You need a prescription CGM — see the Dexcom G7 or FreeStyle Libre 3 sections above.

The Dexcom Stelo is the first FDA-approved over-the-counter continuous glucose monitor in the United States. Approved in 2024, it is available at CVS, Walgreens, Walmart, and Dexcom.com without a prescription, a doctor’s visit, or insurance — for approximately $89/month for a 2-pack of 15-day sensors. It uses the same sensor platform as the prescription Dexcom G7 and transmits readings automatically to the Dexcom app via Bluetooth.

Who Should Choose Dexcom Stelo — And Who Shouldn’t

Stelo Specifications and OTC FDA Approval Status

💬 Real User Experience:
“My doctor said I was ‘pre-diabetic’ but never explained what that meant. Stelo showed me exactly which foods spiked my blood sugar. I lost 15 pounds just by avoiding those foods—no medication needed.”
— Jennifer L., pre-diabetes diagnosis

Stelo Monthly Cost Without Insurance (2026)

How to get started with Dexcom Stelo — no doctor’s visit required:

1. Order online at Dexcom.com/stelo, or pick up at CVS, Walgreens, or Walmart in the pharmacy aisle — no prescription counter visit needed
2. Download the free “Stelo by Dexcom” app (iOS or Android) before your sensor arrives
3. Apply the sensor to the back of your upper arm following the in-app instructions — 30-minute warm-up begins automatically
4. Readings appear in the app continuously; the app provides trend arrows, daily pattern summaries, and alerts if glucose drops below your set threshold

Note from Dr. Das: Stelo is a meaningful first step for patients with prediabetes or non-insulin Type 2 diabetes who have been unable to access CGM technology due to cost or prescription barriers. It does not replace a prescription CGM for insulin users. If your glucose patterns on Stelo suggest hypoglycemic episodes or sustained hyperglycemia, bring the data to your physician — it may support a prior authorization case for a prescription device.

Best CGM for Athletes and Active Users: Medtronic Guardian 4 Review

FDA Approval Status: Approved for diabetes management
Prescription Required: Yes

Why Guardian 4 for Active Lifestyle and Exercise Optimization

Guardian 4 Specifications and FDA Clearance (K210691)

Exercise Mode and Closed-Loop Integration with MiniMed 780G

• Exercise Safety: Predictive low glucose alerts reduce hypoglycemia during physical activity
• Recovery Monitoring: Real-time data shows post-exercise glucose patterns
• Glycemic Variability: Helps identify optimal pre-exercise glucose targets

Strengths:

• Predictive alerts warn 10-60 minutes before glucose trends become problematic
• Designed for active use with reinforced adhesive
• Integration with Medtronic insulin pump systems
• Exercise mode adjusts insulin delivery based on activity
• Proven reliability in high-intensity use

Limitations:

• 2-hour warm-up time (longest in category)
• Limited standalone smartphone functionality
• Best performance requires MiniMed insulin pump pairing
• 7-day sensor duration (shorter than competitors)
• Requires pump prescription for full integration

Guardian 4 Monthly Cost: With and Without Insurance

Note: Best value when integrated with Medtronic MiniMed 780G insulin pump system for closed-loop exercise management.

Ready to Get Started with Tandem T? Here’s How:

Step 1: Verify Insurance Coverage (15 minutes)
Call the number on your insurance card and ask: “Do you cover Medtronic Guardian 4 as durable medical equipment or pharmacy benefit? What’s my copay? Do I need prior authorization?”
Tip: Medicare Part B covers CGMs for insulin users as of 2024. Medicaid coverage varies by state.

Step 2: Get a Prescription (1 doctor visit)
Your doctor needs to prescribe a CGM and provide documentation of your diabetes diagnosis + current treatment. Questions to ask your doctor: Use our downloadable checklist below.

Step 3: Choose Where to Order

• Through insurance: DME (durable medical equipment) supplier or pharmacy benefit
• Out-of-pocket: Manufacturer website- Medtronic Guardian 4 , Amazon, or major pharmacy chains
• Compare pricing: DME suppliers often cheaper with insurance; pharmacies faster without insurance

Step 4: Check for Savings Programs

• Medtronic Guardian 4 manufacturer patient assistance
• Pharmacy discount cards (GoodRx, SingleCare) if paying out-of-pocket
• Ask about trial programs: Some manufacturers offer first sensor free

Can’t decide yet? Save this comparison (print or email yourself) and discuss with your doctor at your next appointment.

Full CGM Comparison Table: MARD, Sensor Life, Cost, and Coverage (2026)

The five continuous glucose monitors compared in this physician review differ meaningfully on clinical accuracy (MARD), sensor wear duration, prescription
requirement, closed-loop compatibility, and monthly cost. The table below consolidates all primary decision variables in one place, based on FDA 510(k)
pivotal trial data and 2026 insurance pricing as of June 2026.

CGM Device	Warm-Up Time	Notes
Dexcom G7	30 minutes	Fastest in category; same platform as Stelo
Dexcom Stelo	30 minutes	OTC; no prescription required
FreeStyle Libre 3	60 minutes	Real-time Bluetooth alerts activate after warm-up
Medtronic Guardian 4	2 hours	Insert before sleep on first night to avoid missed daytime readings

MARD vs. Blood Glucose Meter Accuracy: A Direct Comparison

MARD (Mean Absolute Relative Difference) measures how closely a CGM reading matches a laboratory blood glucose reference. An 8.2% MARD — the Dexcom G7’s figure per FDA 510(k) K213369 — means that if your true blood glucose is 150 mg/dL, the device may display a reading between 138 and 162 mg/dL. The FDA requires MARD ≤10% for non-adjunctive use. Traditional blood glucose meters achieve approximately 5–6% MARD;laboratory analyzers achieve approximately 0%.

If your true blood glucose is 150 mg/dL and your CGM has an 8.2% MARD, the device may display a reading between 138 and 162 mg/dL. At 7.9% MARD (FreeStyle Libre 3), the same true reading may display between 138 and 162 mg/dL — the difference at this glucose level is clinically minimal. The accuracy difference between 7.9% and 8.2% MARD is more meaningful in the hypoglycemic range (below 70 mg/dL), where precision has direct safety implications.

FDA accuracy threshold: The FDA requires a MARD of ≤10% for non-adjunctive CGM use — meaning you can make treatment decisions, including insulin dosing, based on the CGM reading alone without a confirming finger stick. All three prescription CGMs reviewed here meet this threshold.

Why CGM Readings Differ From Finger Sticks: The Interstitial Fluid Lag

CGM sensors measure glucose in interstitial fluid — the fluid surrounding cells in the subcutaneous tissue — not in blood directly. Because glucose equilibrates between blood and interstitial fluid, CGM readings typically lag behind blood glucose by 5 to 15 minutes.

This lag is clinically significant during rapid glucose changes:

• After a meal: Blood glucose rises faster than interstitial glucose. Your CGM may show 110 mg/dL when your blood glucose is already 145 mg/dL.
• During rapid descent: Blood glucose may drop to 68 mg/dL (hypoglycemia) while your CGM still reads 80 mg/dL.
• During stable periods: The lag is negligible — CGM readings are accurate within MARD parameters.

This is why CGMs provide trend arrows alongside readings. A reading of 120 mg/dL with a rapid-descent arrow (↓↓) requires a different response than 120 mg/dL with a flat trend (→) — and is why finger stick confirmation is recommended when symptoms don’t match the CGM reading.

Time in Range vs. HbA1c: Which Metric Should Guide Your CGM Choice?

HbA1c measures average blood glucose over approximately 90 days. It remains the standard diagnostic metric for diabetes management, but it cannot capture glycemic variability — the pattern of highs and lows that CGM technology is specifically designed to reveal.

Time in Range (TIR) measures the percentage of time glucose stays within a target range (typically 70–180 mg/dL for most adults with diabetes). The American Diabetes Association’s 2024 Standards of Care recommend a TIR target of >70% for most adults with Type 1 or Type 2 diabetes.

For patients with HbA1c at target but frequent hypoglycemic episodes — a common pattern in tightly controlled Type 1 diabetes — TIR data from a CGM often drives medication adjustments that HbA1c alone would not reveal.

The monthly cost of a continuous glucose monitor varies significantly based on your insurance tier, whether you qualify for Medicare, and whether you choose a prescription or OTC device. The table below reflects 2026 pricing as of June 2026.

Prices updated June 2026. Actual costs depend on your specific plan and deductible.

CGM Prior Authorization: What Your Doctor Needs to Submit

Medicare Part B covers prescription CGMs for beneficiaries who meet all of the following criteria per CMS Local Coverage Determination L33822:

• Use insulin in any form (as of 2023 policy expansion)
• Test blood glucose at least 4 times daily
• Have a documented diabetes diagnosis in their medical record
• Obtain the device from a Medicare-enrolled DME supplier

OTC devices, including the Dexcom Stelo, are not covered under current Medicare policy.

Most commercial insurance plans require prior authorization before covering a prescription CGM. Your physician’s office initiates this process — but knowing what they need to submit can reduce approval time from weeks to days.

What to ask your doctor’s office to include in the prior authorization:

• CPT code A9277 (CGM sensor, per session) and A9278 (CGM receiver, if applicable)
• Your diabetes diagnosis ICD-10 code: E11.65 (Type 2 diabetes with hyperglycemia), E10.649 (Type 1 with hypoglycemia), or your applicable code
• Documentation of current diabetes treatment (insulin regimen, oral agents, or diet-managed)
• HbA1c trend from your most recent lab results
• Reference to ADA 2024 Standards of Care recommending CGM for your patient category

Medicare prior authorization: Medicare Part B covers CGMs under the Durable Medical Equipment benefit for beneficiaries who use insulin and self-test blood glucose at least 4 times daily. Submit via a Medicare-enrolled DME supplier; your physician must complete a CMN (Certificate of Medical Necessity).

What to Do If Insurance Denies CGM Coverage (78% of Denials Are Overturned)

78% of CGM insurance denials are overturned when patients submit the correct documentation. Here is exactly what to provide.

If your first appeal is denied: Request an external review — an independent organization reviews the denial outside your insurance company. External appeals overturn approximately 40% of denials that survive internal appeal, per Kaiser Family Foundation 2023 analysis.

Free resource: The American Diabetes Association provides a free CGM coverage appeal letter template at diabetes.org — search “CGM coverage appeal.”

Dexcom G7 vs. FreeStyle Libre 3: Full Accuracy and Cost Comparison (2026)

Notes:

• All prescription CGMs may have Medicare/insurance coverage with documentation
• Annual costs are estimates without insurance coverage
• MARD = Mean Absolute Relative Difference (lower is more accurate)

FreeStyle Libre 2 vs. FreeStyle Libre 3: Is the Upgrade Worth It?

Direct answer: The FreeStyle Libre 3 is the better device for most users — it is more accurate (7.9% vs. 9.4% MARD), transmits readings automatically without scanning, and provides real-time Bluetooth alerts. The Libre 2 remains the better choice for elderly patients who do not use a smartphone and rely on the dedicated reader device.

When Libre 2 is still the right choice:

The Libre 2 includes a dedicated reader device — a standalone scanner the size of a credit card that does not require a smartphone. This makes it the preferred option for elderly patients who do not use a smartphone, patients in settings where phone use is restricted, and caregivers who want a simpler device with fewer app dependencies.

When to upgrade to Libre 3:

If you currently use the Libre 2 and scan your sensor multiple times per day to check readings, the Libre 3 eliminates this step entirely. Glucose readings transmit automatically every minute to your phone. Real-time alerts for high or low glucose require no user action. The accuracy improvement (1.5 percentage points in MARD) is clinically meaningful in the hypoglycemic range. Most commercial insurance plans that covered Libre 2 will cover Libre 3 at the same tier.

Note: Libre 2 sensors and Libre 3 sensors are not interchangeable. If you switch, you need a new prescription specifying “FreeStyle Libre 3” — your pharmacy may dispense Libre 2 if the prescription says only “FreeStyle Libre.”

Step 1 — Determine Your Diabetes Management Category

Type 1 Diabetes + Intensive Insulin Therapy:

• Consider: Tandem t:slim X2 + Control-IQ (automated insulin delivery)
• Alternative: Dexcom G7 (standalone CGM with manual insulin dosing)

Type 2 Diabetes Using Insulin:

• Consider: FreeStyle Libre 3 (longest sensor duration, cost-effective)
• Alternative: Dexcom G7 (fastest warm-up, most accurate)

Type 2 Diabetes Not Using Insulin:

• Consider: Dexcom Stelo (OTC, no prescription needed)
• Alternative: FreeStyle Libre 3 (if prescription accessible)

Active Lifestyle/Athletes with Diabetes:

• Consider: Medtronic Guardian 4 (exercise modes, predictive alerts)
• Alternative: Dexcom G7 (real-time sharing, fast warm-up)

Step 2 — Assess Cost and Insurance Coverage

Medicare Part B Beneficiaries:

• Verify coverage criteria (insulin use, testing frequency ≥4/day)
• Most prescription CGMs covered with documentation
• Dexcom Stelo (OTC) not typically covered

Commercial Insurance:

• Check formulary for preferred CGM brands
• Obtain prior authorization before ordering
• Appeal denials with clinical documentation

No Insurance/High Deductible:

• Dexcom Stelo: Lowest out-of-pocket cost
• FreeStyle Libre 3: Lower cost than Dexcom G7
• Manufacturer assistance programs may reduce costs

Step 3 — Consider Integration Needs

Insulin Pump Users:

• Tandem t:slim X2 requires Dexcom G6 integration
• Medtronic MiniMed 780G requires Guardian 4 integration
• Check compatibility before purchasing

Smartphone-Only Users:

• Dexcom G7: No receiver required
• FreeStyle Libre 3: No receiver required
• Dexcom Stelo: Smartphone required (no receiver option)

Family Glucose Sharing:

• Dexcom G7: Up to 10 followers
• FreeStyle Libre 3: Share data via LibreView
• Guardian 4: Limited sharing (primarily pump-focused)

Step 4 — Evaluate Lifestyle Factors

Sensor Change Frequency Preference:

• 14-15 days: FreeStyle Libre 3, Dexcom Stelo
• 10 days: Dexcom G7
• 7 days: Guardian 4

Warm-up Time Sensitivity:

• 30 minutes: Dexcom G7, Dexcom Stelo
• 60 minutes: FreeStyle Libre 3
• 2 hours: Guardian 4

Adhesive Sensitivity:

• All CGMs may cause skin reactions
• Trial period recommended before bulk purchasing
• Discuss alternatives with healthcare provider if reactions occur

Best CGM for Parents Monitoring a Child with Type 1 Diabetes

Prioritize:

• Remote monitoring capability (Dexcom G7 and Guardian Connect allow parents to see child’s glucose from their own phone—critical for overnight monitoring or when child is at school)
• Predictive alerts (warnings 20 minutes before lows give you time to intervene before crisis)
• Durability (kids are active; Dexcom G7 adhesive withstands swimming, sports, sweat better than competitors)

Best choice: Dexcom G7 (FDA-approved for ages 2+, includes “Follow” app for up to 10 caregivers to monitor simultaneously)

Best CGM for Elderly Parents with Type 2 Diabetes

Direct answer: The FreeStyle Libre 2 is the best CGM for elderly patients who do not use a smartphone — it includes a dedicated reader device that obtains readings with a simple scan, requires no app, and costs less than any prescription alternative without insurance.

For elderly patients who do use a smartphone or have a family caregiver managing the app, the FreeStyle Libre 3 is the upgrade — it transmits readings automatically every minute without any scanning, and the LibreLink app can be shared with a caregiver’s phone via the LibreLinkUp feature, allowing real-time remote monitoring.

Features to prioritize when choosing a CGM for an elderly parent:

• Reader device availability: Elderly patients with limited smartphone comfort benefit from Libre 2’s dedicated reader — a single-button device that reads glucose with a one-second scan
• Alert sharing: FreeStyle LibreLinkUp (Libre 2 and Libre 3) and Dexcom Follow (G7) allow a family caregiver to receive real-time alerts on their own phone — critical for patients living alone
• Adhesive tolerance: Elderly patients with thinner skin may experience more adhesive reactions; discuss barrier wipes (such as Skin Tac) with their physician
• Cognitive simplicity: Fewer buttons, fewer app steps, and larger font displays (reader device) reduce burden for patients with mild cognitive impairment

Questions to discuss with your parent’s physician before ordering:

1. Does my parent use insulin? (If yes, a prescription CGM is required — Stelo is not appropriate)
2. Does my parent qualify for Medicare CGM coverage? (Reduces out-of-pocket cost to near zero with proper DME enrollment)
3. Does my parent have any skin sensitivities or adhesive allergies? (Affects sensor placement and rotation guidance)
4. Can we set up caregiver app sharing before the first sensor is applied? (LibreLinkUp and Dexcom Follow require a caregiver account linked in advance)

Questions to Discuss with Your Loved One’s Doctor:

• What happens if they’re hospitalized—can they continue using their personal CGM?
• Can they apply the sensor themselves, or will a caregiver need to do it every 10-14 days?
• If cognitive decline is a concern, which device has the simplest interface?
• Does insurance cover extra supplies for errors during learning period?

Your First Week Using a CGM: What to Expect

Day 1: Insertion and Activation

• Insertion takes 30-60 seconds (watch manufacturer video first—it helps!)
• Sensor needs 30-60 minute warm-up period before first reading
• Common concern: “It feels weird”—this is normal and disappears within 24 hours as you forget it’s there

Days 2-3: Learning the App

• Spend 10 minutes exploring the app features (don’t try to master everything at once)
• Set your target range with your doctor’s guidance (typically 70-180 mg/dL)
• Tip: Don’t panic over every high or low reading yet—you’re still learning your patterns

Days 4-7: Understanding Your Patterns

• Notice which foods cause spikes (everyone is different—you might be surprised)
• Observe your overnight patterns (this is data you’ve never had before)
• Take screenshots of interesting patterns to discuss with your doctor

Week 2+: Making Adjustments

• Small changes based on data (timing of meals, exercise, medication)
• Share reports with your healthcare team
• Join online communities (r/diabetes, Beyond Type 1) to compare experiences

When to Call Support vs. Troubleshoot Yourself:

Call manufacturer support if:

• Sensor fails within first 24 hours
• Readings are 50+ mg/dL off from finger stick (after warm-up period)
• Adhesive causes severe skin reaction
• App won’t connect to sensor after multiple restart attempts

Troubleshoot yourself first if:

• Readings seem slightly off (wait 24 hours—sensors stabilize after initial day)
• Adhesive edges lifting (use overlay patches like Skin Grip)
• Forgot to scan/check app (set phone reminders until it becomes habit)

Normal learning curve: Most users feel comfortable after 2-3 sensor changes (3-6 weeks).

Clinical Evidence and References

Device Accuracy and Clinical Trials:

1. FDA 510(k) Summaries: Dexcom G7 (K213369), FreeStyle Libre 3 (K221503), Guardian 4 (K210691)
   
2. Wadwa RP, et al. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2023.
   
3. Brown SA, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381:1707-1717.
   
4. Forlenza GP, et al. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children with Type 1 Diabetes in an At-Home Randomized Crossover Study. Diabetes Care. 2018.
   

Type 2 Diabetes CGM Evidence:

5. Bolinder J, et al. Novel Glucose-Sensing Technology and Hypoglycaemia in Type 1 Diabetes: A Multicentre, Non-masked, Randomised Controlled Trial. Lancet. 2016;388:2254-2263.
   
6. Haak T, et al. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: The REPLACE Trial. Diabetes Ther. 2017;8:55-73.
   

Medicare Coverage and Guidelines:

7. Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD): Glucose Monitors (L33822). Revised 2023.
   
8. CMS Manual System Pub 100-03, Medicare National Coverage Determinations, Section 40.2: Blood Glucose Testing.
   

Professional Guidelines:

9. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1).
   
10. Peters AL, et al. Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016.
    

Accuracy Standards:

U.S. Food and Drug Administration. Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use: Guidance for Industry and FDA Staff. 2020.

ISO 15197:2013. In Vitro Diagnostic Test Systems — Requirements for Blood-Glucose Monitoring Systems for Self-Testing in Managing Diabetes Mellitus.

Medical Disclaimer and Selection Process

Important Medical Information

This content is educational only and does not constitute medical advice.

• Glucose monitor selection should be made in consultation with your healthcare provider
• Individual device suitability depends on diabetes type, treatment regimen, and personal factors
• Prescription requirements vary by device and jurisdiction
• Insurance coverage varies significantly by plan and medical necessity criteria

For complete medical oversight and review standards, see our About page.